UK's Midatech Makes Desperate Cash Call
Executive Summary
The Oxford-based biotech needs more money and fast to fund development of MTD201, which it believes offers a number of competitive advantages over Novartis blockbuster Sandostatin LAR.
Topics
- Subjects
- Financing
- Clinical Trials
- Commercial
- Manufacturing
- Therapy Areas
- Cancer
- Industries
- BioPharmaceutical
Latest Headlines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
SC124553
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.
All fields are required.
SC124553
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.